drugset / Trial / NCT06360237
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Summary
The purpose of the Expanded Access Program is to provide pre-approval access of olezarsen to eligible patients with Familial Chylomicronemia Syndrome (FCS).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olezarsen | Antisense oligonucleotide | 80 mg | Subcutaneous |